نتایج جستجو برای: dapagliflozin

تعداد نتایج: 927  

Journal: :European Heart Journal 2022

Abstract Background Trastuzumab has improved the prognosis in patients with HER2-positive breast cancer, but it can induce left ventricular dysfunction reduced ejection fraction or HF during treatment. Dapagliflozin is a SGLT2i cardio-renal benefits. In DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes Heart Failure) trial, sodium-glucose cotransporter 2 inhibitor dapagliflozin decrease...

Journal: :European Heart Journal Supplements 2022

Abstract Background Large cardiovascular (CV) trials enrolling patients with type 2 diabetes showed that sodium glucose co-transporter-2 inhibitors (SGLT2i) significantly decreased heart failure (HF) hospitalization, both in or without a history of HF. Accordingly, DAPA-HF (Dapagliflozin and Prevention Adverse Outcomes Heart Failure) demonstrated the efficacy dapagliflozin, for reduction CV dea...

Journal: :Journal of Current Pharma Research 2018

Journal: :European Journal of Heart Failure 2019

Journal: :European Heart Journal 2022

Abstract Background The SGLT2 inhibitors dapagliflozin and empagliflozin have an evolving role in heart failure therapy. Observational data suggest a lower risk of atrial fibrillation (AF) for patients on inhibitors. So far, it is unclear whether this related to direct antiarrhythmic potential or just marker improved function. Experimental the impact SGTL2 electrophysiology scarce. Purpose This...

2018
Takao Sato Yoshifusa Aizawa Sho Yuasa Shohei Kishi Koichi Fuse Satoshi Fujita Yoshio Ikeda Hitoshi Kitazawa Minoru Takahashi Masahito Sato Masaaki Okabe

BACKGROUND Glycosuria produced by sodium-glucose co-transporter-2 (SGLT-2) inhibitors is associated with weight loss. SGLT-2 inhibitors reportedly might reduce the occurrence of cardiovascular events. Epicardial adipose tissue (EAT) is a pathogenic fat depot that may be associated with coronary atherosclerosis. The present study evaluated the relationship between an SGLT-2 inhibitor (dapagliflo...

Journal: :Eskisehir Medical Journal Eskisehir City Hospital 2023

Aim: This study aimed to examine the effects of sodium glucose cotransporter 2 inhibitors (SGLT-2i) on lipid levels at 12 weeks follow-up in newly diagnosed hypertensive (NDHT) patients with type diabetes mellitus (T2DM). Methodsː retrospective study, 236 NDHT T2DM were included. The SGLT-2i group consisted who received (empagliflozin or dapagliflozin) addition stable triple combination treatme...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید